External Research Grants for U.S. Investigators

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) - BI Cares Foundation

Suggest an update

Grant amount: Up to US $1,000,000

Deadline: Rolling

Applicant type: Research Scientist Doctor Postdoctoral Researcher Faculty

Funding uses: Biomedical

Location of project: United States

Location of residency: United States

View website    Save

About this funder:

Loading...

Overview:

External Research Grants

The mission of the Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) External Research Grants Program for U.S. Investigators is to support the advancement of scientific knowledge regarding BIPI products and therapeutic areas of interest, through support of novel research proposals in areas of scientific interest to BIPI.

External Research Grants Program for U.S. Investigators

The External Research Grants Program is designed to enable research that has the potential to improve the treatment of disease, patient outcomes and the quality of healthcare. Support is awarded based on the scientific merit of each proposal received and reviewed through BIPI's External Research Grants Program processes. The External Research Grants Program is offered to all U.S. academic and community based scientists, individually or though consortia.

The External Research Grants Program allows interested investigators to submit proposals for consideration where they may independently execute research as an Investigator Initiated Study (IIS) or to work collaboratively as External Collaborative Research (ECR) to execute their research concept. BIPI does not assume regulatory responsibility for either type of external research, and thus investigators are expected to serve as Sponsor-Investigator for either IIS or ECR studies. While BIPI may consider applications for studies outside the approved indication, should such a study be approved, the investigator may have to file an IND with the FDA.

Investigator Initiated Studies (IIS) Program for U.S. Investigators

The Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) IIS Program is offered to all qualified U.S. academic and community based scientists or consortiums who are interested in independently proposing and conducting their own research. BIPI may provide drug product and/or financial support for approved IIS. BIPI does not serve as the Regulatory Sponsor for IIS.

In general, IIS are not “registrational” studies and may be “proof of concept” or “exploratory” in nature. The budget for such studies is usually less than $1 million, should reflect “fair market value” for all costs and cannot include direct salary support for the principal investigator.

External Collaborative Research Program for U.S. Investigators

BIPI’s External Collaborative Research (ECR) Program is offered to all qualified U.S. academic and community based scientists or consortiums that are interested in proposing a research study and wish to collaborate with BIPI to further develop a protocol and analyze and publish the results. In addition to providing intellectual contributions, BIPI may provide drug product and/or financial support for approved ECR. BIPI does not serve as the Regulatory Sponsor for ECR.

The preliminary budget for ECR studies should reflect “fair market value” for all costs and cannot include direct salary support for the principal investigator. Budgets for ECR will be further negotiated pending finalization of the collaborative protocol.

BIPI’s Areas of Research Interest

Oncology

  • Solid Tumors
    • For drug only support, a submitted synopsis will be evaluated on an ongoing basis for strategic interest. Where interested, Boehringer Ingelheim will request a full proposal submission. All proposals will be reviewed on an ongoing basis; generally monthly.
    • For requests involving financial support, Boehringer Ingelheim will evaluate a synopsis application on an ongoing basis for strategic interest. Where interested, Boehringer Ingelheim will request a full proposal submission.
  • Afatinib IIS & ECR Objectives
    • Safety and efficacy of alternate dosing regimens (e.g., lower starting dose, treatment holidays, etc.)
    • Tumors driven by dysregulation of ErbB family members other than EGFR (e.g., HER2, HER3, HER4)
      • non-T790M acquired resistance to 1st/2nd generation EGFR TKIs
      • acquired resistance to 3rd generation TKIs following either first or second line use

Cardiometabolism

  • Type 2 Diabetes - Key areas of interest for External Collaborative Research: 
    • Gain real-world evidence on utilization, effectiveness and safety of empagliflozin and/or linagliptin in patients with diabetes and established cardiovascular disease
    • Understand real-world utilization of empagliflozin and/or linagliptin in patients with diabetes and heart failure

Respiratory

  • Asthma
    • Evaluation of gaps in pharmacological management strategy for treatment of mild, moderate and severe asthma.
    • Assess impact of asthma in adult, adolescent and pediatric patients on Healthcare Resource Utilization HCRU (outpatient visits, ER visits, asthma exacerbation hospitalizations and associated costs)
    • Evaluate asthma pharmacotherapy received before and after asthma related hospitalization
    • Evaluate the impact of ICS dose and HCRU
  • COPD
    • Assess STIOLTO effectiveness in COPD population with early (Mild/Moderate) disease including impact on HCRU (Outpatient visits, ER visits, AECOPD Hospitalizations, All cause and COPD related 30/90 Re-Admission, exacerbation treatment, adverse reactions, and associated COPD costs).
    • Describe proportion and characteristics (e.g. Exacerbation history) of patients with COPD treated with ICS- containing therapy including triple therapy (any combination LAMA/LABA/ICS).
    • Evaluate clinical phenotypes and their impact on inhaler selection and use in COPD and contribution to patient preferences, outcomes and adherence (i.e. Suboptimal PIFR, Disease Severity)
    • Evaluate institution COPD disease management programs that include the Respimat as inhaler platform and its impact on HCRU
  • ILD/IPF
    • Clinical studies investigating newer tools for IPF/ILD screening, earlier diagnosis or disease assessment
    • Clinical studies investigating ILD therapies non-competing with Nintedanib
    • Clinical trials studying ILD subgroups that were not covered in other Boehringer Ingelheim clinical trials

You can learn more about this opportunity by visiting the funder's website.

Eligibility:

  • IIS: The Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) IIS Program is offered to all qualified U.S. academic and community based scientists or consortiums who are interested in independently proposing and conducting their own research.
  • ECR: BIPI’s External Collaborative Research (ECR) Program is offered to all qualified U.S. academic and community based scientists or consortiums that are interested in proposing a research study and wish to collaborate with BIPI to further develop a protocol and analyze and publish the results.